

# 2019 Future of Interstitial Cystitis R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2B35C8B86D9EN.html>

Date: February 2019

Pages: 50

Price: US\$ 2,199.00 (Single User License)

ID: 2B35C8B86D9EN

## Abstracts

The global demand for Interstitial Cystitis treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Interstitial Cystitis pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Interstitial Cystitis pipeline companies from advancing their products into Phase 3 or Phase 4.

### Interstitial Cystitis Report Description-

The 2019 pipeline study on Interstitial Cystitis pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Interstitial Cystitis pipeline compounds.

The Interstitial Cystitis pipeline guide presents information on all active drugs currently being developed for Interstitial Cystitis. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Interstitial Cystitis pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Interstitial Cystitis drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Interstitial Cystitis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Interstitial Cystitis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Interstitial Cystitis pipeline report includes-

An overview of Interstitial Cystitis disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Interstitial Cystitis pipeline

Company wise list of Interstitial Cystitis pipeline

Mechanism of Action wise Interstitial Cystitis pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

## **REASONS TO BUY**

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Interstitial Cystitis pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Interstitial Cystitis pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Interstitial Cystitis pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

## Contents

### **1. TABLE OF CONTENTS**

- 1.1 List of Tables
- 1.2 List of Figures

### **2. GLOBAL INTERSTITIAL CYSTITIS PIPELINE OVERVIEW**

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

### **3. EXECUTIVE SUMMARY**

- 3.1 Interstitial Cystitis Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
  - 3.2.1 Pre-clinical
  - 3.2.2 Discovery
  - 3.2.3 Phase
  - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
  - 3.3.1 Phase
  - 3.3.2 Pre-registration
- 3.4 Companies involved in Interstitial Cystitis pipeline, H1- 2019
- 3.5 Mechanism of Action wise Interstitial Cystitis Pipeline Candidates

### **4 ALIVIO THERAPEUTICS INC INTERSTITIAL CYSTITIS PIPELINE DETAILS**

- 4.1 Alivio Therapeutics Inc Business Profile
- 4.2 Alivio Therapeutics Inc Interstitial Cystitis Drug Details
- 4.3 Drug Snapshot
  - 4.3.1 Originator
  - 4.3.2 Collaborator/Co-Developer
  - 4.3.3 Route of Administration
  - 4.3.4 Orphan Drug/Fast Track/Special Designation
  - 4.3.5 Geography
  - 4.3.6 Type of Molecular Entity
  - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

## **5 ASTELLAS PHARMA INC INTERSTITIAL CYSTITIS PIPELINE DETAILS**

- 5.1 Astellas Pharma Inc Business Profile
- 5.2 Astellas Pharma Inc Interstitial Cystitis Drug Details
- 5.3 Drug Snapshot
  - 5.3.1 Originator
  - 5.3.2 Collaborator/Co-Developer
  - 5.3.3 Route of Administration
  - 5.3.4 Orphan Drug/Fast Track/Special Designation
  - 5.3.5 Geography
  - 5.3.6 Type of Molecular Entity
  - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

## **6 GLYCOMIRA THERAPEUTICS INC INTERSTITIAL CYSTITIS PIPELINE DETAILS**

- 6.1 GlycoMira Therapeutics Inc Business Profile
- 6.2 GlycoMira Therapeutics Inc Interstitial Cystitis Drug Details
- 6.3 Drug Snapshot
  - 6.3.1 Originator
  - 6.3.2 Collaborator/Co-Developer
  - 6.3.3 Route of Administration
  - 6.3.4 Orphan Drug/Fast Track/Special Designation
  - 6.3.5 Geography
  - 6.3.6 Type of Molecular Entity
  - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

## **7 IDERA PHARMACEUTICALS INC INTERSTITIAL CYSTITIS PIPELINE DETAILS**

- 7.1 Idera Pharmaceuticals Inc Business Profile
- 7.2 Idera Pharmaceuticals Inc Interstitial Cystitis Drug Details
- 7.3 Drug Snapshot
  - 7.3.1 Originator
  - 7.3.2 Collaborator/Co-Developer
  - 7.3.3 Route of Administration
  - 7.3.4 Orphan Drug/Fast Track/Special Designation
  - 7.3.5 Geography
  - 7.3.6 Type of Molecular Entity
  - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

## **8 KYORIN PHARMACEUTICAL CO LTD INTERSTITIAL CYSTITIS PIPELINE DETAILS**

- 8.1 Kyorin Pharmaceutical Co Ltd Business Profile
- 8.2 Kyorin Pharmaceutical Co Ltd Interstitial Cystitis Drug Details
- 8.3 Drug Snapshot
  - 8.3.1 Originator
  - 8.3.2 Collaborator/Co-Developer
  - 8.3.3 Route of Administration
  - 8.3.4 Orphan Drug/Fast Track/Special Designation
  - 8.3.5 Geography
  - 8.3.6 Type of Molecular Entity
  - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

## **9 LIPELLA PHARMACEUTICALS INC INTERSTITIAL CYSTITIS PIPELINE DETAILS**

- 9.1 Lipella Pharmaceuticals Inc Business Profile
- 9.2 Lipella Pharmaceuticals Inc Interstitial Cystitis Drug Details

## 9.3 Drug Snapshot

9.3.1 Originator

9.3.2 Collaborator/Co-Developer

9.3.3 Route of Administration

9.3.4 Orphan Drug/Fast Track/Special Designation

9.3.5 Geography

9.3.6 Type of Molecular Entity

9.3.7 Current Status

## 9.4 Drug Overview

## 9.5 Drug Mechanism of Action

## 9.6 Clinical/Pre-clinical Trial Details

## 9.7 Latest Drug Developments

# **10 MIRAE CELL BIO CO LTD INTERSTITIAL CYSTITIS PIPELINE DETAILS**

## 10.1 Mirae Cell Bio Co Ltd Business Profile

## 10.2 Mirae Cell Bio Co Ltd Interstitial Cystitis Drug Details

## 10.3 Drug Snapshot

10.3.1 Originator

10.3.2 Collaborator/Co-Developer

10.3.3 Route of Administration

10.3.4 Orphan Drug/Fast Track/Special Designation

10.3.5 Geography

10.3.6 Type of Molecular Entity

10.3.7 Current Status

## 10.4 Drug Overview

## 10.5 Drug Mechanism of Action

## 10.6 Clinical/Pre-clinical Trial Details

## 10.7 Latest Drug Developments

# **11 PIERRE FABRE PHARMACEUTICALS INC INTERSTITIAL CYSTITIS PIPELINE DETAILS**

## 11.1 Pierre Fabre Pharmaceuticals Inc Business Profile

## 11.2 Pierre Fabre Pharmaceuticals Inc Interstitial Cystitis Drug Details

## 11.3 Drug Snapshot

11.3.1 Originator

11.3.2 Collaborator/Co-Developer

11.3.3 Route of Administration



- 11.3.4 Orphan Drug/Fast Track/Special Designation
- 11.3.5 Geography
- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

## **12 UCB SA INTERSTITIAL CYSTITIS PIPELINE DETAILS**

- 12.1 UCB SA Business Profile
- 12.2 UCB SA Interstitial Cystitis Drug Details
- 12.3 Drug Snapshot
  - 12.3.1 Originator
  - 12.3.2 Collaborator/Co-Developer
  - 12.3.3 Route of Administration
  - 12.3.4 Orphan Drug/Fast Track/Special Designation
  - 12.3.5 Geography
  - 12.3.6 Type of Molecular Entity
  - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

## **13 URIGEN PHARMACEUTICALS INC INTERSTITIAL CYSTITIS PIPELINE DETAILS**

- 13.1 Urigen Pharmaceuticals Inc Business Profile
- 13.2 Urigen Pharmaceuticals Inc Interstitial Cystitis Drug Details
- 13.3 Drug Snapshot
  - 13.3.1 Originator
  - 13.3.2 Collaborator/Co-Developer
  - 13.3.3 Route of Administration
  - 13.3.4 Orphan Drug/Fast Track/Special Designation
  - 13.3.5 Geography
  - 13.3.6 Type of Molecular Entity
  - 13.3.7 Current Status
- 13.4 Drug Overview

- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

## **14 XIGEN SA INTERSTITIAL CYSTITIS PIPELINE DETAILS**

- 14.1 Xigen SA Business Profile
- 14.2 Xigen SA Interstitial Cystitis Drug Details
- 14.3 Drug Snapshot
  - 14.3.1 Originator
  - 14.3.2 Collaborator/Co-Developer
  - 14.3.3 Route of Administration
  - 14.3.4 Orphan Drug/Fast Track/Special Designation
  - 14.3.5 Geography
  - 14.3.6 Type of Molecular Entity
  - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

## **15. LATEST INTERSTITIAL CYSTITIS DRUG PIPELINE DEVELOPMENTS, 2019**

## **16. APPENDIX**

- 16.1 About Us
- 16.2 Sources and Methodology
- 16.3 Contact Information

## I would like to order

Product name: 2019 Future of Interstitial Cystitis R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2B35C8B86D9EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2B35C8B86D9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

